Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Reply.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.Journal of pharmacological sciences · 2023
   Review
2. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy.BMC infectious diseases · 2022
   Article
3. The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines.Health policy and technology · 2022
   Article
4. Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol.BMC pregnancy and childbirth · 2022
   Article
5. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.Emerging microbes & infections · 2021
   Article
6. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.The Lancet. Infectious diseases · 2021
   Article
7. Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France.The Lancet regional health. Europe · 2021
   Article

Corrections and comments

• Comment on
  Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.2021

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as